Immune-Cell-Based Therapy for COVID-19: Current Status

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.

Cite

CITATION STYLE

APA

Wang, Y., Liang, Q., Chen, F., Zheng, J., Chen, Y., Chen, Z., … Li, X. (2023, November 1). Immune-Cell-Based Therapy for COVID-19: Current Status. Viruses. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/v15112148

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free